Cell and Gene Therapy Today—June 11, 2026

This week’s Gene and Cell Therapy update highlights regulatory advances, registrational trial progress, strategic partnerships, platform expansion, and continued momentum across rare disease, oncology, and autoimmune disease programs.

In Today’s Newsletter

Dive deeper

🧬 Sangamo explores strategic alternatives [1] [US • 08 Jun 2026]

https://investor.sangamo.com/news-releases/news-release-details/sangamo-therapeutics-announces-exploration-strategic
Context: Sangamo Therapeutics has retained Raymond James to evaluate strategic alternatives while maintaining its genomic medicine pipeline.
Key point: The company highlighted its BLA-ready Fabry disease gene therapy program, zinc finger platform, STAC-BBB capsid technology, and MINT genome engineering platform.
Implication: Signals pipeline investment and modality expansion.

🧠 Neurogene completes dosing in NGN-401 registrational trial [2] [US • 08 Jun 2026]

https://www.businesswire.com/news/home/20260608913151/en/Neurogene-Announces-Successful-Completion-of-Dosing-in-Embolden-Registrational-Trial-of-NGN-401-for-Rett-Syndrome
Context: Embolden is a registrational trial evaluating NGN-401, a one-time gene therapy candidate for Rett syndrome.
Key point: Neurogene completed dosing of 25 participants, exceeding its original enrollment target.
Implication: May influence prescriber choice and payer reviews pending full data.

🏥 Biogen gains FDA Breakthrough Therapy Designation for salanersen [3] [US • 04 Jun 2026]

https://investors.biogen.com/news-releases/news-release-details/biogens-salanersen-receives-fda-breakthrough-therapy-designation
Context: Salanersen is an investigational once-yearly antisense oligonucleotide for spinal muscular atrophy (SMA).
Key point: FDA granted Breakthrough Therapy Designation based on early clinical evidence from a Phase 1b study.
Implication: May accelerate regulatory interactions and clinical development.

🧪 Syntax Bio and Mayo Clinic partner on diabetes cell therapy [4] [US • 09 Jun 2026]

https://www.businesswire.com/news/home/20260609294223/en/Syntax-Bio-Announces-Collaboration-with-Mayo-Clinic-to-Advance-Pancreatic-Cell-Therapy-for-Type-1-Diabetes
Context: The collaboration focuses on stem cell-derived pancreatic beta cell therapies for type 1 diabetes.
Key point: Syntax Bio will apply its Cellgorithm platform while Mayo Clinic contributes translational and preclinical expertise.
Implication: Signals pipeline investment and modality expansion.

🧫 Imviva receives FDA IND clearance for CTA313 [5] [US • 09 Jun 2026]

https://www.imvivabio.com/news_detail/imviva-biotech-receives-fda-investigational-new-drug-approval-for-cta313-a-dual-targeted-cd19bcma-allogeneic-car-t-cell-therapy-for-autoimmune-diseases.html
Context: CTA313 is a dual-targeted CD19/BCMA allogeneic CAR-T therapy for autoimmune diseases.
Key point: FDA cleared a Phase 1b basket study in systemic lupus erythematosus, progressive multiple sclerosis, and autoimmune encephalitis.
Implication: Signals pipeline investment and modality expansion.

🔬 Cartesian licenses in vivo CAR-T platform technology [6] [US • 09 Jun 2026]

https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-strategic-licensing-agreement
Context: Cartesian Therapeutics licensed WestGene’s targeted lipid nanoparticle technology for in vivo CAR-T development.
Key point: The companies plan a Phase 1 study in myasthenia gravis using Cartesian’s mRNA payloads and WestGene delivery technology.
Implication: Signals pipeline investment and modality expansion.

🎯 Lyell updates LYL273 safety profile in colorectal cancer [7] [US • 08 Jun 2026]

https://www.globenewswire.com/news-release/2026/06/08/3307886/0/en/Lyell-Immunopharma-Provides-Update-on-Safety-Profile-of-LYL273-in-Relapsed-or-Refractory-Metastatic-Colorectal-Cancer-and-Amends-Phase-1-Trial-to-Phase-1-2-Expansion.html
Context: LYL273 is a GCC-targeted CAR-T candidate for relapsed or refractory metastatic colorectal cancer.
Key point: Gastrointestinal prophylaxis reduced Grade ≥2 diarrhea/colitis and the study was amended to support seamless Phase 1/2 expansion.
Implication: May influence prescriber choice and payer reviews pending full data.

🦠 Artiva highlights EULAR data and RMAT designation [8] [US • 08 Jun 2026]

https://www.globenewswire.com/news-release/2026/06/08/3307910/0/en/artiva-biotherapeutics-highlights-allonk-data-presented-at-eular-2026-fda-rmat-designation-in-refractory-rheumatoid-arthritis-and-webcast-today.html
Context: AlloNK (AB-101) is an allogeneic NK cell therapy being evaluated in autoimmune diseases.
Key point: Artiva reported clinical activity across rheumatoid arthritis, Sjögren disease, and systemic sclerosis, and received FDA RMAT designation in refractory rheumatoid arthritis.
Implication: May influence prescriber choice and payer reviews pending full data.

Why it matters

Regulatory momentum continues across rare disease and autoimmune cell and gene therapy programs.
In vivo cell engineering approaches are attracting increased partnership activity.
Autoimmune disease remains a major growth area for next-generation CAR-T and NK cell therapies.
Several companies are positioning programs for registrational studies or accelerated regulatory pathways.
Strategic and financing decisions are becoming increasingly important as companies seek efficient paths to commercialization.

📚 View the full Rare Disease archive on our research hub page

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🧰 See our full range of services. Discover how we can help you.

🎯 Catch up on the Top Cell and Gene Therapy news from the past two weeks, curated by the LucidQuest team.

🎬 Watch on YouTube.

FAQ

What is NGN-401 and what happened this week?

NGN-401 is Neurogene’s investigational gene therapy for Rett syndrome. The company completed dosing in its registrational Embolden trial and expects topline data in 2H 2027. [2]

Why is Biogen’s salanersen designation important?

FDA Breakthrough Therapy Designation can support more intensive regulatory engagement and potentially accelerate development timelines for salanersen in SMA. [3]

What is Sangamo evaluating through its strategic review?

Sangamo is exploring strategic alternatives while highlighting assets including ST-920 for Fabry disease, STAC-BBB, zinc finger technologies, and the MINT platform. [1]

How does Cartesian’s approach differ from conventional CAR-T therapy?

Cartesian and WestGene aim to generate CAR-T activity in vivo using mRNA payloads and targeted lipid nanoparticles, potentially avoiding traditional ex vivo manufacturing. [6]

What diseases are being studied with Imviva’s CTA313?

The FDA-cleared basket study includes systemic lupus erythematosus, progressive multiple sclerosis, and autoimmune encephalitis. [5]

What is AlloNK being developed for?

Artiva is evaluating AlloNK with rituximab in refractory rheumatoid arthritis and other B-cell-driven autoimmune diseases. [8]

Entities / Keywords

Sangamo Therapeutics (SGMO), ST-920, isaralgagene civaparvovec, STAC-BBB, MINT
Neurogene (NGNE), NGN-401, Embolden, Rett syndrome
Biogen (BIIB), salanersen, SMA, Breakthrough Therapy Designation
Syntax Bio, Mayo Clinic, pancreatic beta cells, type 1 diabetes
Imviva Biotech, CTA313, CD19/BCMA CAR-T, autoimmune disease
Cartesian Therapeutics, WestGene, in vivo CAR-T, Descartes-08
Lyell Immunopharma, LYL273, GCC CAR-T, metastatic colorectal cancer
Artiva Biotherapeutics, AlloNK, AB-101, rheumatoid arthritis, RMAT